Application of 4-carbamoyl-1-.beta.-D-ribofuranosyl imidazolium-5-olate to the treatment of multiple sclerosis
AssigneeAsahi Kasei Kogyo Kabushiki Kaisha
InventorsTakahiko Saida, Kyoko Saida
Life of this patent
Estimating the term…
Abstract
A composition for the treatment or prevention of multiple sclerosis is disclosed. It comprises mizoribine (4-carbamoyl-1-.beta.-D-ribofuranosyl imidazolium-5-olate) as the effective component. It is a safe drug, exhibiting a minimal degree of side-effects, and thus can be administered over a long period of time. Administration of the drug, usually 1-20 mg/kg (body weight) per day for adults, improves the functional disturbances of multiple sclerosis.
Claims3
A method of treating multiple sclerosis which comprises administering an effective amount of 4-carbamoyl-1-.beta.-D-ribofuranosyl imidazolium-5-olate to a patient suffering from multiple sclerosis.
Dependencies are inferred from the claim text.